Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma's wholly-owned subsidiary in the US, joins GPhA

London, 24 May 2016 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, today announces that Michael Raya, Chief Executive Officer of West-Ward Pharmaceuticals, Hikma’s wholly-owned subsidiary in the US, will join the Board of Directors of the Generic Pharmaceutical Association (GPhA).

Press Release Corporate 24 May 2016

Michael Raya said: 
“The GPhA’s Board and professional staff are terrific stewards of the industry. I am honored to add my voice to GPhA’s leadership on critical issues of medicine access and affordability.”

Chip Davis, President and CEO, GPhA, said: 
“Michael Raya is a proven industry leader whose addition to our Board will accelerate our work with Congress, the FDA, stakeholders and others to ensure that generic drugs and biosimilars continue providing millions of Americans with safe, effective and more affordable alternatives to costly brand products.”

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.